ReviewDiscovery medicine2018
Triggers of inflammatory myopathy: insights into pathogenesis.
Review in Discovery medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 47 citations in OpenAlex.
- An update on autoantibodies in the idiopathic inflammatory myopathies.Nature reviews. Rheumatology · 2025Review
- Acute Viral-Induced Myopathy Following Covid-19.European journal of case reports in internal medicine · 2025Article
- Construction and validation of a diagnostic model for dermatomyositis based on the LASSO algorithm.Central-European journal of immunology · 2025Article
- Idiopathic Inflammatory Myopathies-Associated Interstitial Lung Disease in Adults.Tuberculosis and respiratory diseases · 2025Article
- Inclusion body myositis, viral infections, and TDP-43: a narrative review.Clinical and experimental medicine · 2024Review
- COVID-19 vaccine-associated myositis: a comprehensive review of the literature driven by a case report.Immunologic research · 2023Review
- The complement system and human autoimmune diseases.Journal of autoimmunity · 2023Review
- Necrotizing autoimmune myositis following coronavirus disease 2019 infection: a case report.Journal of medical case reports · 2022Article
- A case of anti-HMGCR myopathy triggered by sodium/glucose co-transporter 2 (SGLT2) inhibitors.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Article
- The composition of the lung microbiome differs between patients with dermatomyositis and rheumatoid arthritis associated with interstitial lung disease.FEBS open bio · 2022Article
- Life-Threatening Myositis in a Patient WithJTO clinical and research reports · 2022Article
- Autoantibodies in the pathogenesis of idiopathic inflammatory myopathies: Does the endoplasmic reticulum stress response have a role?Frontiers in immunology · 2022Review
- Review
- Article
- Dermatomyositis: immunological landscape, biomarkers, and potential candidate drugs.Clinical rheumatology · 2021Article
- Anti-HMGCR myopathy misdiagnosed as motor neuron disease and complicated with COVID-19 infection.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Article
- COVID-19 IgG-related autoimmune inflammatory necrotizing myositis.BMJ case reports · 2021Article
- Delayed-onset Necrotizing Myositis following COVID-19 Infection.European journal of case reports in internal medicine · 2021Article
- Ten genes are considered as potential biomarkers for the diagnosis of dermatomyositis.PloS one · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The inflammatory myopathies, which include dermatomyositis, polymyositis, and the immune-mediated necrotizing myopathies, are a heterogeneous group of autoimmune diseases that manifest with muscle, skin, or lung damage. Collectively, these autoimmune diseases result from loss of tolerance to a select group of self-antigens, although the precise mechanism through which this occurs is not known. Infection, malignancy, and certain medications including statins and the immune checkpoint inhibitors used in cancer therapy have been identified as potential immunologic triggers of the inflammatory myopathies. Some of these triggers are classically associated with specific myositis-specific autoantibodies (MSAs). The strong association between certain triggers and MSAs provides insights into how an immunologic event can lead to loss of tolerance to specific self-antigens, resulting in autoimmune disease. In this review, we discuss the proposed triggers of the inflammatory myopathies and their associations with MSAs, and provide insights into how these triggers may result in the inflammatory myopathies.
Indexed as
Identifiers
29579414PMC5921929W2806451946What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.